Literature DB >> 33420074

Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma.

Jason Behary1,2,3, Nadia Amorim1,2, Xiao-Tao Jiang1,2, Anita Raposo1,2, Lan Gong1,2, Emily McGovern1,2, Ragy Ibrahim3, Francis Chu4, Carlie Stephens3, Hazem Jebeili3, Vincenzo Fragomeli5, Yen Chin Koay6, Miriam Jackson1,2, John O'Sullivan6, Martin Weltman5, Geoffrey McCaughan7,8, Emad El-Omar1,2,3, Amany Zekry9,10,11.   

Abstract

The gut microbiota is reported to modulate the immune response in hepatocellular carcinoma (HCC). Here, we employ metagenomic and metabolomic studies to characterise gut microbiota in patients with non-alcoholic fatty liver disease (NAFLD) related cirrhosis, with or without HCC, and evaluate its effect on the peripheral immune response in an ex vivo model. We find that dysbiosis characterises the microbiota of patients with NAFLD-cirrhosis, with compositional and functional shifts occurring with HCC development. Gene function of the microbiota in NAFLD-HCC supports short chain fatty acid production, and this is confirmed by metabolomic studies. Ex vivo studies show that bacterial extracts from the NAFLD-HCC microbiota, but not from the control groups, elicit a T cell immunosuppressive phenotype, characterised by expansion of regulatory T cells and attenuation of CD8 + T cells. Our study suggest that the gut microbiota in NAFLD-HCC is characterised by a distinctive microbiome/metabolomic profile, and can modulate the peripheral immune response.

Entities:  

Year:  2021        PMID: 33420074     DOI: 10.1038/s41467-020-20422-7

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  50 in total

1.  Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.

Authors:  Zobair M Younossi; Munkhzul Otgonsuren; Linda Henry; Chapy Venkatesan; Alita Mishra; Madeline Erario; Sharon Hunt
Journal:  Hepatology       Date:  2015-10-24       Impact factor: 17.425

2.  Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome.

Authors:  Shin Yoshimoto; Tze Mun Loo; Koji Atarashi; Hiroaki Kanda; Seidai Sato; Seiichi Oyadomari; Yoichiro Iwakura; Kenshiro Oshima; Hidetoshi Morita; Masahira Hattori; Masahisa Hattori; Kenya Honda; Yuichi Ishikawa; Eiji Hara; Naoko Ohtani
Journal:  Nature       Date:  2013-06-26       Impact factor: 49.962

3.  NAFLD: The evolving landscape.

Authors:  Jacob George; Quentin Anstee; Vlad Ratziu; Arun Sanyal
Journal:  J Hepatol       Date:  2017-12-06       Impact factor: 25.083

4.  Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.

Authors:  Francesca Romana Ponziani; Sherrie Bhoori; Chiara Castelli; Lorenza Putignani; Licia Rivoltini; Federica Del Chierico; Maurizio Sanguinetti; Daniele Morelli; Francesco Paroni Sterbini; Valentina Petito; Sofia Reddel; Riccardo Calvani; Chiara Camisaschi; Anna Picca; Alessandra Tuccitto; Antonio Gasbarrini; Maurizio Pompili; Vincenzo Mazzaferro
Journal:  Hepatology       Date:  2018-07-10       Impact factor: 17.425

5.  Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.

Authors:  Rohit Loomba; Victor Seguritan; Weizhong Li; Tao Long; Niels Klitgord; Archana Bhatt; Parambir Singh Dulai; Cyrielle Caussy; Richele Bettencourt; Sarah K Highlander; Marcus B Jones; Claude B Sirlin; Bernd Schnabl; Lauren Brinkac; Nicholas Schork; Chi-Hua Chen; David A Brenner; William Biggs; Shibu Yooseph; J Craig Venter; Karen E Nelson
Journal:  Cell Metab       Date:  2017-05-02       Impact factor: 27.287

6.  Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE2-Mediated Suppression of Antitumor Immunity.

Authors:  Tze Mun Loo; Fumitaka Kamachi; Yoshihiro Watanabe; Shin Yoshimoto; Hiroaki Kanda; Yuriko Arai; Yaeko Nakajima-Takagi; Atsushi Iwama; Tomoaki Koga; Yukihiko Sugimoto; Takayuki Ozawa; Masaru Nakamura; Miho Kumagai; Koichi Watashi; Makoto M Taketo; Tomohiro Aoki; Shuh Narumiya; Masanobu Oshima; Makoto Arita; Eiji Hara; Naoko Ohtani
Journal:  Cancer Discov       Date:  2017-02-15       Impact factor: 39.397

7.  Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.

Authors:  Rohit Loomba; Victor Seguritan; Weizhong Li; Tao Long; Niels Klitgord; Archana Bhatt; Parambir Singh Dulai; Cyrielle Caussy; Richele Bettencourt; Sarah K Highlander; Marcus B Jones; Claude B Sirlin; Bernd Schnabl; Lauren Brinkac; Nicholas Schork; Chi-Hua Chen; David A Brenner; William Biggs; Shibu Yooseph; J Craig Venter; Karen E Nelson
Journal:  Cell Metab       Date:  2019-09-03       Impact factor: 31.373

8.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.

Authors:  Tomi Akinyemiju; Semaw Abera; Muktar Ahmed; Noore Alam; Mulubirhan Assefa Alemayohu; Christine Allen; Rajaa Al-Raddadi; Nelson Alvis-Guzman; Yaw Amoako; Al Artaman; Tadesse Awoke Ayele; Aleksandra Barac; Isabela Bensenor; Adugnaw Berhane; Zulfiqar Bhutta; Jacqueline Castillo-Rivas; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Lalit Dandona; Rakhi Dandona; Subhojit Dey; Daniel Dicker; Huyen Phuc; Donatus U. Ekwueme; Maysaa El Sayed Zaki; Florian Fischer; Thomas Fürst; Jamie Hancock; Simon I. Hay; Peter Hotez; Sun Ha Jee; Amir Kasaeian; Yousef Khader; Young-Ho Khang; Anil Kumar; Michael Kutz; Heidi Larson; Alan Lopez; Raimundas Lunevicius; Reza Malekzadeh; Colm McAlinden; Toni Meier; Walter Mendoza; Ali Mokdad; Maziar Moradi-Lakeh; Gabriele Nagel; Quyen Nguyen; Grant Nguyen; Felix Ogbo; George Patton; David M. Pereira; Farshad Pourmalek; Mostafa Qorbani; Amir Radfar; Gholamreza Roshandel; Joshua A Salomon; Juan Sanabria; Benn Sartorius; Maheswar Satpathy; Monika Sawhney; Sadaf Sepanlou; Katya Shackelford; Hirbo Shore; Jiandong Sun; Desalegn Tadese Mengistu; Roman Topór-Mądry; Bach Tran; Vasiliy Vlassov; Stein Emil Vollset; Theo Vos; Tolassa Wakayo; Elisabete Weiderpass; Andrea Werdecker; Naohiro Yonemoto; Mustafa Younis; Chuanhua Yu; Zoubida Zaidi; Liguo Zhu; Christopher J. L. Murray; Mohsen Naghavi; Christina Fitzmaurice
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

9.  A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease.

Authors:  Cyrielle Caussy; Anupriya Tripathi; Greg Humphrey; Shirin Bassirian; Seema Singh; Claire Faulkner; Ricki Bettencourt; Emily Rizo; Lisa Richards; Zhenjiang Z Xu; Michael R Downes; Ronald M Evans; David A Brenner; Claude B Sirlin; Rob Knight; Rohit Loomba
Journal:  Nat Commun       Date:  2019-03-29       Impact factor: 14.919

10.  Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.

Authors:  Zhigang Ren; Ang Li; Jianwen Jiang; Lin Zhou; Zujiang Yu; Haifeng Lu; Haiyang Xie; Xiaolong Chen; Li Shao; Ruiqing Zhang; Shaoyan Xu; Hua Zhang; Guangying Cui; Xinhua Chen; Ranran Sun; Hao Wen; Jan P Lerut; Quancheng Kan; Lanjuan Li; Shusen Zheng
Journal:  Gut       Date:  2018-07-25       Impact factor: 23.059

View more
  48 in total

1.  A Novel Angiogenesis-Related Prognostic Signature Associated with the Hepatocellular Carcinoma Immune Microenvironment and Survival Outcome.

Authors:  Xin Jiang; Yushuang Xu; Di Chen; Mengmeng Wang; Mengjun Qiu; Lina Xiong; Li Zhang; Honglu Yu; Zhifan Xiong
Journal:  Int J Gen Med       Date:  2022-01-07

Review 2.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

Review 3.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

Review 4.  The Gut Microbiome and Hepatocellular Carcinoma: Implications for Early Diagnostic Biomarkers and Novel Therapies.

Authors:  Yongbo Kang; Yue Cai; Ying Yang
Journal:  Liver Cancer       Date:  2021-12-21       Impact factor: 12.430

5.  The Absence of STING Ameliorates Non-Alcoholic Fatty Liver Disease and Reforms Gut Bacterial Community.

Authors:  Qiang Zhang; Qiongyun Chen; Changsheng Yan; Chunyan Niu; Jingping Zhou; Jingjing Liu; Yang Song; Fei Zhou; Yanyun Fan; Jianlin Ren; Hongzhi Xu; Bangzhou Zhang
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

6.  Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment.

Authors:  Kai Markus Schneider; Antje Mohs; Wenfang Gui; Eric J C Galvez; Lena Susanna Candels; Lisa Hoenicke; Uthayakumar Muthukumarasamy; Christian H Holland; Carsten Elfers; Konrad Kilic; Carolin Victoria Schneider; Robert Schierwagen; Pavel Strnad; Theresa H Wirtz; Hanns-Ulrich Marschall; Eicke Latz; Benjamin Lelouvier; Julio Saez-Rodriguez; Willem de Vos; Till Strowig; Jonel Trebicka; Christian Trautwein
Journal:  Nat Commun       Date:  2022-07-08       Impact factor: 17.694

7.  A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepatocellular Carcinoma.

Authors:  Da Mao; Meihong Xu; Qiyu Jiang; Huiwei Sun; Fang Sun; Ruichuang Yang; Yantao Chai; Xiaojuan Li; Boan Li; Yong Li
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

8.  Association of Increased Circulating Acetic Acid With Poor Survival in Pseudomonas aeruginosa Ventilator-Associated Pneumonia Patients.

Authors:  Xiaoling Qi; Li Zhang; Jing Xu; Zheying Tao; Xiaoli Wang; Yuzhen Qiu; Tingting Pan; Zhaojun Liu; Hongping Qu; Ruoming Tan; Jialin Liu
Journal:  Front Cell Infect Microbiol       Date:  2021-04-29       Impact factor: 5.293

Review 9.  Consideration of Gut Microbiome in Murine Models of Diseases.

Authors:  Chunye Zhang; Craig L Franklin; Aaron C Ericsson
Journal:  Microorganisms       Date:  2021-05-14

Review 10.  Cancer and hepatic steatosis.

Authors:  R Paternostro; W Sieghart; M Trauner; M Pinter
Journal:  ESMO Open       Date:  2021-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.